Drugs / ChAdOx-1-S[recombinant]
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT06189040 | May → Nov 2021 | COVID-19 | University of Antwerp | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT04894435 Comparator | May 2021 → Nov 2024 overdue | COVID-19 | Canadian Immunization Research Network | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05710783 Comparator | Nov → Dec 2022 | COVID-19 | Laboratorio Avi-Mex, S.A. de C.V. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2023-04-14 | AstraZeneca | Results ECCMID data reinforces AstraZeneca’s commitment to transform protection for the most vulnerable by advancing science in vaccines and immune therapies astrazeneca.com ↗
Persistently high immunogenicity and between-country differences driven by hybrid immunity from primary-series AZD2816 or AZD1222 (ChAdOx1 nCoV-19) and Omicron infections |
| 2022-11-01 | AstraZeneca | Regulatory Vaxzevria receives full Marketing Authorisation in the EU for the prevention of COVID-19 astrazeneca.com ↗
AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted full Marketing Authorisation (MA) in the European Union (EU). |
| 2022-05-23 | AstraZeneca | Regulatory Vaxzevria approved in the EU as third dose booster against COVID-19 astrazeneca.com ↗
AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the European Medicine Agency (EMA) as a third dose booster in adults. |
| 2022-01-13 | AstraZeneca | Results New Vaxzevria data further support its use as third dose booster astrazeneca.com ↗
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha and Gamma variants following third dose booster with Vaxzevria |
| 2021-12-23 | AstraZeneca | Results Vaxzevria significantly boosted antibody levels against Omicron astrazeneca.com ↗
AstraZeneca’s Vaxzevria (ChAdOx1-S [Recombinant]) significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a third dose booster, according to data from a new laboratory study. |
| 2021-05-21 | AstraZeneca | Regulatory AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan astrazeneca.com ↗
AstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]) , formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisation of individuals aged 18 years and older, to prevent COVID-19 caused by SARS-CoV-2. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-04-14 | AstraZeneca | ECCMID data reinforces AstraZeneca’s commitment to transform protection for the most vulnerable by advancing science in vaccines and immune therapies astrazeneca.com ↗ |
| 2022-11-01 | AstraZeneca | Vaxzevria receives full Marketing Authorisation in the EU for the prevention of COVID-19 astrazeneca.com ↗ |
| 2022-05-23 | AstraZeneca | Vaxzevria approved in the EU as third dose booster against COVID-19 astrazeneca.com ↗ |
| 2022-01-13 | AstraZeneca | New Vaxzevria data further support its use as third dose booster astrazeneca.com ↗ |
| 2021-12-23 | AstraZeneca | Vaxzevria significantly boosted antibody levels against Omicron astrazeneca.com ↗ |
| 2021-05-21 | AstraZeneca | AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan astrazeneca.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx1-S [Recombinant] | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06189040 ↗ |
| Known as | ChAdOx1 nCOV-19 | “The ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine is authorized to be given in two doses one month to 12 weeks apart.” NCT04894435 ↗1“Single dose IM administration of ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine” NCT05710783 ↗ |
| Modality | Vaccine | “The ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine” NCT04894435 ↗ |
| Route | Intramuscular | “ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle” NCT04894435 ↗ |